VisionPoint Advisory Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

VisionPoint Advisory Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$226K	Buy	+975	New	+$241K	0.04%	416

Other funds holding JAZZ

Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return

CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return

Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return

Parrish Capital Kennesaw, Georgia $103M AUM 35.11% 1-Year Est. Return

Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Bank of New Hampshire Laconia, New Hampshire $463M AUM 23.57% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

YHB Investment Advisors West Hartford, Connecticut $1.59B AUM 21.04% 1-Year Est. Return

VisionPoint Advisory Group's JAZZ Position: Q3 2026 in Review

VisionPoint Advisory Group opened a new position in Jazz Pharmaceuticals (JAZZ) in Q3 2026: 975 shares worth $226K. The stake represents 0.04% of the portfolio and ranks #416 among its holdings.

21 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.

VisionPoint Advisory Group held 975 shares of Jazz Pharmaceuticals worth $226K as of Q3 2026.
Jazz Pharmaceuticals was a new VisionPoint Advisory Group position in Q3 2026.
Jazz Pharmaceuticals made up 0.04% of VisionPoint Advisory Group's portfolio in Q3 2026, its #416 holding.
21 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.

Based on VisionPoint Advisory Group's 13F filing for Q3 2026, filed 9 Oct 2026.